Navigation Links
Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
Date:2/4/2009

LEXINGTON, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) (the "Company") today announced its consolidated results of operations for the first quarter of fiscal 2009, ended December 31, 2008.

The Company reported revenues of $26.4 million and a consolidated net loss of $7.6 million or $0.10 per share for the quarter ended December 31, 2008. This compares to revenues of $16.4 million and a consolidated net loss of $14.7 million or $0.19 per share for the quarter ended December 31, 2007.

At December 31, 2008, the Company had consolidated cash and cash equivalents totaling approximately $125.6 million.

Financial Results

Total consolidated revenues for the quarter ended December 31, 2008 were $26.4 million, an increase of 61% from the $16.4 million reported for the quarter ended December 31, 2007. The primary components of revenue for the quarter ended December 31, 2008 were $13.0 million from the recognition of revenue associated with the SANCTURA(R) brand, $6.8 million from sales of VANTAS(R), and $5.9 million from sales of SUPPRELIN(R) LA.

Cost of product revenue for the quarter ended December 31, 2008 was $6.5 million, an increase of 12% from the $5.9 million reported for the quarter ended December 31, 2007. Cost of product revenue in the current quarter relates primarily to costs associated with the SANCTURA brand, including royalties on sales of SANCTURA and SANCTURA XR(TM) that are reimbursed by Allergan, and costs associated with VANTAS and SUPPRELIN LA.

Research and development expenses for the quarter ended December 31, 2008 were $5.2 million, a decrease of 19% from the $6.4 million reported for the quarter ended December 31, 2007. Marketing, general and administrative expenses for the quarter ended December
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
2. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
3. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
4. Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
5. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
6. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
7. Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
8. Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
9. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
10. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
11. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... ATLANTA, Dec. 7 Results of two ... formulation of the antiepileptic drug (AED) Vimpat® for ... oral AED therapy is temporarily not feasible. ... the 63rd annual meeting of the American Epilepsy ... intravenous Vimpat in the institutional setting. ,, One ...
(Date:12/7/2009)... Dec. 7 Interleukin Genetics, Inc. (NYSE Amex: ... by the State of New York,s Department of Health ... PST Genetic Test that determines predisposition to severe periodontal ... in all other States in the U.S. However, ... monitors the accuracy and reliability of results of laboratory ...
(Date:12/7/2009)... Health Service (NHS), which manages 500 hospitals and over ... of an engaged staff: healthier and happier patients. As ... of care, many NHS hospitals are teaming up with ... train hospital leaders. ,, "Staff engagement is essential to ... Weeks, policy manager for NHS Employers, an organisation that ...
(Date:12/7/2009)... a Texas Wind Integration project team including Drummond Group Inc., ... grid demonstration project. Drummond Group,s role is overseeing the interoperability ... strong support from the project stakeholders. , ... ... The Department of Energy has selected a Texas ...
(Date:12/7/2009)... their 2009 tax return by using the free tax calculator. Answer simple questions ... ... -- Taxpayers can estimate their 2009 tax return by using the free tax ... child could understand it. No more waiting or worrying about how much the ... handy tool everyone can use., , , Find out right now with ...
Breaking Medicine News(10 mins):Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 2Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 3Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 4Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 5Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 2Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 3Health News:The NHS to Improve Patient Care by Better Engaging Staff 2Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 2Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 3Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 4Health News:2009 Free Tax Return Calculator 2
... randomized trial published in Lancet Oncology, laparoscopic surgery// could ... the right, left, and sigmoid colon. The multicenter COLOR ... the short-term benefits of laparoscopic colectomy for cancer as ... been assigned to laparoscopic surgery and 621 patients to ...
... of deaths from advanced prostate cancer is to catch// them ... that effective screening can prevent as much as 35% deaths. ... men and is the second leading cause of death by ... are discovered when they have already spread to other organs. ...
... determining factor and may play a more dominant role than exercise// ... ,Now we know why some people never gain weight or increase ... to their hearts content!! , ,The July 8, 2005, ... looking at 28 pairs of identical twins in whom one was ...
... meat consumes more oil and gas and can be a ... Calverd, writing in this month's ‘Physics World’ said: ,"Worldwide reduction ... in the Kyoto treaty seems to carry fewer political unknowns ... giving up pork chops, lamb cutlets and chicken burgers would ...
... University of British Columbia had showed that noise// might be ... efficiency, more so when that is effectively used to help ... thought as the one sensation that comes in our way ... is often related to the disturbances that cause distractions in ...
... It is now official - eating fish is good for the ... medicine at the University of Minnesota Medical School has found ... body is less and there is also a lower risk of ... fatty acids in the fishes that are lean varieties such as ...
Other Medicine News:Health News:Screening For Prostate Cancer May Reduce Mortality Rate 2Health News:Genes More Important Than Exercise for Bad Cholesterol 2
(Date:12/4/2009)... The U.S. Food and Drug Administration (FDA) today approved ... the treatment of schizophrenia and manic or mixed episodes ... years old. ,, The updated Zyprexa label states ... for weight gain and hyperlipidemia in adolescents compared to ...
(Date:12/4/2009)... Pharmacy announced today that it received accreditation by the ... pharmacy services. For nearly 15 years, Amber Pharmacy has ... the unique needs of specialized conditions. Amber Pharmacy is ... programs. They work with over 170 transplant programs and ...
(Date:12/4/2009)... Dec. 4 Shared Imaging, LLC, an independent ... service programs for hospitals and healthcare providers, is ... Commission,s Accreditation for Ambulatory Health Care, a nationally-recognized, ... safety in patient care. Shared Imaging accreditation is ...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Amber Pharmacy Earns Accreditation From ACHC 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Labor Day Event to Offer Angelenos Unique Opportunity to Learn About Healthcare Reform and Send a Strong Message to Washington D C 21 56265 1Labor Day Event to Offer Angelenos Unique Opportunity to Learn About Healthcare Reform and Send a Strong Message to Washington D C 21 56265 2Surgical scrub solution 3A Its good for patients too 56263 1Surgical scrub solution 3A Its good for patients too 56263 2Surgical scrub solution 3A Its good for patients too 56263 3Surgical scrub solution 3A Its good for patients too 56263 4Perennial vegetation an indicator of desertification in Spain 9792 1Perennial vegetation an indicator of desertification in Spain 9792 2Perennial vegetation an indicator of desertification in Spain 9792 3
... Riverain Medical,s OnGuard(TM) Technology Being Evaluated to Determine ... Common Radiological Procedure Into ... CHICAGO, Nov. 26 Cleveland Clinic and ... study in an ongoing program,to determine whether chest ...
... of VELCADE in front-line, multiple myeloma to be featured ... Society of Hematology ... Inc. (Nasdaq: MLNM ) today announced that new data from,more ... at the 49th ASH Annual Meeting in Atlanta, Georgia, December 8-11,2007. ...
Other Medicine Technology:Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 2Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 3Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 4Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 5Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 6Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 7New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 2New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 4New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 5New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 6
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: